ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1323.5 | 1194.6 | 1190.4 |
| Other income | 8.1 | 106.9 | 12.0 |
| Total income | 1331.6 | 1301.5 | 1202.4 |
| Profit before exceptional items & tax | 153.0 | 248.8 | 130.7 |
| Exceptional items | -6.4 | -3.3 | -27.4 |
| Profit before tax | 148.1 | 245.5 | 106.4 |
| Net profit | 129.3 | 208.1 | 85.6 |
| Operating margin | 11.1% | 18.9% | 8.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +51.10% |
|---|---|
| Net profit, quarter on quarter | -37.90% |
| Revenue, year on year | +11.20% |
BSE results filing, NSE: STAR. Figures extracted from the filing.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹995.80
- Market cap
- ₹9,179 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 14.9×Sector 43.8×
- Promoter holding
- 29.00%+1.09% QoQ
- FII holding
- 27.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Earnings Call Transcript: Key Takeaways
Record Q2 revenue ₹1,430 Cr (+17% YoY), Ex-US overtakes US, but EBITDA margin fell to 17.6% on input costs; US aspiration slips beyond FY28.
Strides Pharma Science Management Change
Strides Pharma's board appointed Biren Gabhawala as Non-Executive Independent Director effective November 1, 2026, for five years. He is a Chartered Accountant with extensive audit and listed-company board experience.
- Execution
- Five-year term effective November 1, 2026
Strides Pharma Science Employee Stock Options
Strides Pharma allotted 7,500 equity shares to an employee exercising options under the Strides ESOP 2016 Plan. Paid-up capital rises to 92,180,214 shares.
Strides Pharma Science Investor Presentation: Key Takeaways
Q2FY27 revenue ₹14,297m (+17.1% YoY), EBITDA ₹2,509m (17.6% margin), reported PAT ₹1,341m (+2.0%). Ex-US revenue surpassed US for the first time; US ~$375m FY28 aspiration pushed beyond FY28.
Strides Pharma Science Results Update
Strides Pharma reported Q2FY27 revenue of ₹14,297m, up 17.1% YoY, and EBITDA of ₹2,509m, up 8.4%, in a press release. Reported PAT rose 2.0% to ₹1,341m.
Strides Pharma Science Q2 FY27 Results: Net Profit ₹134.1 Cr, Up 2.0% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,430 Cr (+17.1% YoY) and net profit of ₹134.1 Cr (+2.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹134.1 Cr · +2.0% YoY